0000920465-20-000032.txt : 20200219
0000920465-20-000032.hdr.sgml : 20200219
20200219164745
ACCESSION NUMBER: 0000920465-20-000032
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200214
FILED AS OF DATE: 20200219
DATE AS OF CHANGE: 20200219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rolke James
CENTRAL INDEX KEY: 0001693858
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36282
FILM NUMBER: 20630576
MAIL ADDRESS:
STREET 1: 10182 TELESIS COURT, 6TH FLOOR
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO
CENTRAL INDEX KEY: 0000920465
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 330361285
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4550 TOWNE CENTRE COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-207-4264
MAIL ADDRESS:
STREET 1: 4550 TOWNE CENTRE COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
wf-form4_158214884842276.xml
FORM 4
X0306
4
2020-02-14
0
0000920465
LA JOLLA PHARMACEUTICAL CO
LJPC
0001693858
Rolke James
C/O LA JOLLA PHARMACEUTICAL COMPANY,
4550 TOWNE CENTRE COURT
SAN DIEGO
CA
92121
0
1
0
0
Chief Scientific Officer
Common Stock
2020-02-14
4
A
0
115
7.14
A
80535
D
Stock Option (Right to Buy)
8.4
2020-02-14
4
A
0
115
0
A
2030-02-14
Common Stock
115.0
115
D
These shares were acquired on 02/14/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.
/s/ Ryan Murr, as attorney-in-fact for James Rolke
2020-02-19